NCT00464802已完成1 期
A Double-Blind, Placebo-Controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Comparison With the Current Formulation in Healthy Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- IV site tolerability and urinary zinc excretion
研究概览
简要总结
The primary objective is to determine the safety and tolerability of the new IV formulation versus the current formulation of MOA-728 focusing on the theoretical potential for infusion-related and formulation-related complications.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
IV site tolerability and urinary zinc excretion
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or PolymyositisDERMATOMYOSITIS OR POLYMYOSITISNCT00533091MedImmune LLC51
已完成
2 期
An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With EpilepsyEpilepsies, PartialEpilepsyNCT00210652SK Life Science, Inc.47
已完成
1 期
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsInflammatory Disorder of the Respiratory TractChronic Obstructive Pulmonary DisorderNCT02307162Verona Pharma plc112
已完成
1 期
Study of NAV-240 in Healthy VolunteersNCT06181786Navigator Medicines, Inc.40
已完成
2 期
Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart FailureAcute Decompensated Heart FailureNCT00839007Nile Therapeutics77